Short ratio of NanoString Technologies, Inc.

3.94
Short ratio is the number of shares sold short divided by the average daily volume.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Short ratio of companies in the Health Care sector on NASDAQ compared to NanoString Technologies, Inc.

NanoString Technologies, Inc. logo

NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.

  • NanoString Technologies, Inc., 530 Fairview Avenue North, Seattle 98109, United States
  • nanostring.com
  • 206-378-6266